How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) released its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG) , Party City Holdco (PRTY) , Washington Prime Group (WPG) , Akorn (AKRXQ) , Akers Biosciences (AKER) , Akebia Therapeutics (AKBA) , Adamis Pharmaceuticals (ADMP) , ADMA Biologics (ADMA) and Acasti Pharma (ACST) .

NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free BLU Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $14.74
▼
$14.75
50-Day Range: $14.42
▼
$14.75
52-Week Range: $6.38
▼
$14.76

Volume: 3.45 million shs
Average Volume: 3.08 million shs
Market Capitalization: $1.87 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get BELLUS Health alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About BELLUS Health Stock (NASDAQ:BLU)

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

BLU Stock News Headlines

March 21, 2024 | msn.com

Deal reached between Dignity Health, Arizona Blue Cross Blue Shield

March 4, 2024 | msn.com

The effects of 'blue light' on human health are still unclear, says panel

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

January 4, 2024 | msn.com

Glowing blue waves off Orange County coast make for thrilling start to New Year

December 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Bluebird Bio (BLUE), United Therapeutics (UTHR)

September 21, 2023 | forbes.com

CBD Dosage: How Much Should You Take?

June 28, 2023 | fool.com

Bellus Health (NASDAQ: BLU)

June 27, 2023 | msn.com

These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

June 25, 2023 | finance.yahoo.com

BLU.TO - BELLUS Health Inc.

June 17, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)

May 10, 2023 | ca.finance.yahoo.com

TSX Stocks in the Healthcare Industry: Which Ones Are Worth Your Money?

May 10, 2023 | finance.yahoo.com

Should You Buy Bellus Health (BLU) After Golden Cross?

May 2, 2023 | theglobeandmail.com

Closing Bell: Bellus Health Inc up on Tuesday (BLU)

April 26, 2023 | theglobeandmail.com

BELLUS Health: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BLU)

April 26, 2023 | finance.yahoo.com

BELLUS Health Announces Meeting Updates

April 21, 2023 | benzinga.com

Moore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law Firm

April 19, 2023 | finance.yahoo.com

Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

April 19, 2023 | theglobeandmail.com

GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family

April 19, 2023 | reuters.com

GSK bets $2 bln on Bellus cough drug to soothe pipeline fears

April 18, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)

April 18, 2023 | theglobeandmail.com

GSK signs deal to buy Canadian drug developer Bellus Health for US$2 billion

April 18, 2023 | finance.yahoo.com

Bellus Health Soars 99% As GSK Joins Buyout Bonanza With $2 Billion Deal

April 18, 2023 | cnbc.com

Stocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and more

April 18, 2023 | bizjournals.com

GSK to buy Canadian biopharm firm Bellus Health for $2 billion

April 18, 2023 | finance.yahoo.com

Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal

April 18, 2023 | finance.yahoo.com

Why BELLUS Health Stock Is Rocketing Higher Today

See More Headlines

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BLU
CUSIP: N/A
CIK: 1259942
Web: www.bellushealth.com
Phone: (450) 680-4500
Fax: 45-0680-4501
Employees: 74
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $0.00
High Stock Price Target: $0.00
Low Stock Price Target: $10,000,000.00
Potential Upside/Downside: +0.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,080,000.00
Net Margins: -578,586.63%
Pretax Margin: -578,226.56%
Return on Equity: -24.27%
Return on Assets: -23.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 33.42
Quick Ratio: 33.42

Sales & Book Value

Annual Sales: $15,000.00
Price / Sales: 124,613.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.09 per share
Price / Book: 4.77

Miscellaneous

Outstanding Shares: 126,812,000
Free Float: 96,162,000
Market Cap: $1.87 billion
Optionable: Not Optionable
Beta: 0.19

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Roberto Francesco Bellini (Age 43)
Pres, CEO & Director
Comp: $790.35k
Mr. Ramzi Benamar (Age 50)
Chief Financial Officer
Comp: $650.48k
Dr. Andreas Orfanos FFPM (Age 64)
M.B.B.Ch, MBA, Chief Operating Officer
Comp: $417.58k
Dr. Denis Garceau Ph.D. (Age 66)
Chief Scientific Officer
Comp: $496.56k
Dr. Catherine M. Bonuccelli M.D. (Age 65)
Chief Medical Officer
Comp: $741.66k
Mr. Daniel Matthews
Director of Investor Relations & Communications
Mr. Tony Matzouranis (Age 50)
Chief Bus. Officer
Mr. Sebastien Roy (Age 47)
Corp. Sec.

Key Competitors

View All Competitors

BLU Stock Analysis - Frequently Asked Questions

How were BELLUS Health's earnings last quarter?: BELLUS Health Inc. (NASDAQ:BLU) released its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.
What other stocks do shareholders of BELLUS Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

This page (NASDAQ:BLU) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BELLUS Health (BLU) Stock Price, News & Analysis

About BELLUS Health Stock (NASDAQ:BLU)

BLU Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BLU Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info